Cargando…
Ex Vivo Treatment with a Novel Synthetic Aminoglycoside NB54 in Primary Fibroblasts from Rett Syndrome Patients Suppresses MECP2 Nonsense Mutations
BACKGROUND: Nonsense mutations in the X-linked methyl CpG-binding protein 2 (MECP2) comprise a significant proportion of causative MECP2 mutations in Rett syndrome (RTT). Naturally occurring aminoglycosides, such as gentamicin, have been shown to enable partial suppression of nonsense mutations rela...
Autores principales: | Vecsler, Manuela, Ben Zeev, Bruria, Nudelman, Igor, Anikster, Yair, Simon, Amos J., Amariglio, Ninette, Rechavi, Gideon, Baasov, Timor, Gak, Eva |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3113846/ https://www.ncbi.nlm.nih.gov/pubmed/21695138 http://dx.doi.org/10.1371/journal.pone.0020733 |
Ejemplares similares
-
Readthrough of nonsense mutations in Rett syndrome: evaluation of novel aminoglycosides and generation of a new mouse model
por: Brendel, Cornelia, et al.
Publicado: (2010) -
Erratum to: Readthrough of nonsense mutations in Rett syndrome: evaluation of novel aminoglycosides and generation of a new mouse model
por: Brendel, Cornelia, et al.
Publicado: (2013) -
Balancing
Nonsense Mutation Readthrough and Toxicity
of Designer Aminoglycosides for Treatment of Genetic Diseases
por: Guchhait, Sandip, et al.
Publicado: (2023) -
A comparative evaluation of NB30, NB54 and PTC124 in translational read-through efficacy for treatment of an USH1C nonsense mutation
por: Goldmann, Tobias, et al.
Publicado: (2012) -
Expanding the MECP2 network using comparative genomics reveals potential therapeutic targets for Rett syndrome
por: Unterman, Irene, et al.
Publicado: (2021)